BRM Targeting Compounds and Associated Methods of Use

A compound of Formula (I):

• 1.PTM—ULM (I)
• or a pharmaceutically acceptable salt or solvate thereof,
• wherein PTM is a moiety of Formula IA:
• wherein
• R1 is a covalent bond, or chemical moiety that links PTM and ULM;
• is a point of attachment to ULM;
• n=0-3;
• each W is independently optionally substituted —CH2—, —C(O)—, —S(O)—, or —S(O)2—;
• wherein when n=2 or 3, only one W is —C(O)—, —S(O)—, or —S(O)2—, and the other W are —CH2— or substituted —CH2—;
• Rc1 and Rd1 are independently H, D, Halo, C1-6 alkyl, C1-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxyl;
• Re3 is H, —C(O)R, or —P(O)(ORg)2;
• wherein Rf and Rg are independently H, C1-4 alkyl, C1-4 substituted alkyl, C3-8 cycloalkyl, C3-8 substituted cycloalkyl, C3-8 heterocycloalkyl, or C3-8 substituted heterocycloalkyl;
• Z and Y are each independently N;
• CRh wherein Rh=H, D, halo, C1-6 alkyl, C1-6 cycloalkyl, C1-3 haloalkyl or absent;
• or, if R1 is attached to Z, then Z is C and Y is N or CRh wherein Rh is H;
• or if R1 is attached to Y, then Y is C and Z is N or CRh wherein Rh is H;
• B is an optionally substituted 5-7 membered cycloalkyl ring, an optionally substituted 5-7 membered aryl ring, an optionally substituted 5-7 membered heteroaryl ring, or an optionally substituted 5-7 membered heterocyclic ring, wherein ring B is fused to ring G through Y and Z;
• and ULM is
• wherein X1 is a bond, —C(O)—, —C(S)—, —CH2—, —CHCF3—, SO2—, —S(O), P(O)Rb— or —P(O)ORb—;
• Rb, is H, D, -C1-C6 alkyl, —C2-C6 alkenyl, -C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;
• and
• each X2 is independently N or CRb, provided that one X2 is a C atom having the attachment point to PTM.